GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Apr 24, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Apr 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on April 24, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any new material risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker executing share purchases
- April 2025 (date) — Reporting period for the transaction
- April 24, 2025 (date) — Date of the announcement
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on GSK plc's transactions in its own shares during the month of April 2025.
Who is acting as GSK's stockbroker for these transactions?
Citigroup Global Markets Limited is acting as GSK's corporate stockbroker for these transactions.
What type of shares did GSK purchase?
GSK purchased its own ordinary shares of 31¼ pence each.
Does the filing specify the number of shares purchased?
No, the filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity in the provided text.
What is GSK's principal executive office address?
GSK's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 24, 2025 regarding GSK plc (GLAXF).